Published in Law and Health Weekly, January 1st, 2005
In the quarter, the company completed a successful public equity financing and continued progress in its drug development program remaining on schedule to file an Investigational New Drug (IND) application by the end of 2004. This IND will seek United States Food and Drug Administration (FDA) approval to evaluate the company's lead product AL-108 in human clinical trials.
Gordon McCauley, president of Allon, said the company has scheduled phase I clinical trials to begin during Q1 2005, subject to FDA approval of the IND. The company...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.